Ankerstar Wealth’s Supernus Pharmaceuticals SUPN Stock Holding History

Ankerstar Wealth’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$569	Hold	11	–	–	﹤0.01%	586
2025 Q4	$547	Buy	+11	New	+$535	﹤0.01%	628

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ankerstar Wealth's SUPN Position: Q1 2026 in Review

Ankerstar Wealth held its Supernus Pharmaceuticals (SUPN) position steady in Q1 2026 at 11 shares worth $569. The position accounts for ﹤0.01% of the portfolio, ranked #586.

Ankerstar Wealth first reported a position in SUPN in Q4 2025 and has held it in 2 quarters since. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

Ankerstar Wealth held 11 shares of Supernus Pharmaceuticals worth $569 as of Q1 2026.
Ankerstar Wealth left its Supernus Pharmaceuticals share count unchanged in Q1 2026.
Supernus Pharmaceuticals made up ﹤0.01% of Ankerstar Wealth's portfolio in Q1 2026, its #586 holding.
Ankerstar Wealth first reported a position in Supernus Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Ankerstar Wealth's 13F filing for Q1 2026, filed 14 May 2026.